Actively Recruiting
Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation
Led by Beykoz University · Updated on 2025-04-20
60
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
Sponsors
B
Beykoz University
Lead Sponsor
U
Uskudar University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to determine whether Cognitive Remediation Therapy (CRT) can improve attention, memory, and emotional regulation in people with schizophrenia. CRT is a structured program that includes exercises to strengthen cognitive skills such as problem-solving, working memory, and emotion regulation. The study will recruit 60 participants: 30 individuals with schizophrenia and 30 healthy individuals of similar age and gender. Those with schizophrenia will be randomly assigned to either receive CRT or be placed on a waitlist without therapy. All participants will undergo non-invasive brain activity (EEG) and emotional response (GSR) recordings before and after the therapy. The study's main question is: Does participating in a 12-week CRT program improve brain-based markers of attention and emotional regulation in people with schizophrenia? Additional tests, such as memory and emotion recognition tasks and self-report questionnaires, will help assess changes in thinking skills and emotional well-being. The study may help better understand how CRT affects both brain function and quality of life in schizophrenia.
CONDITIONS
Official Title
Cognitive Remediation Therapy for Schizophrenia: Effects on EEG and Emotional Regulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with schizophrenia according to DSM-5 criteria (schizophrenia group)
- Age between 18 and 55 years
- Clinically stable with no hospitalization or medication change within 1 month (schizophrenia group)
- Minimum primary school education (schizophrenia group)
- Able to provide informed consent
- Right-handed for EEG protocol consistency
- No history of psychiatric or neurological disorders (healthy control group)
- Age- and gender-matched to schizophrenia group (healthy control group)
- No current medication affecting central nervous system (healthy control group)
You will not qualify if you...
- Current or past substance use disorder within the past year
- Comorbid neurological illness such as epilepsy or traumatic brain injury
- Current use of benzodiazepines or medications significantly affecting cognitive function
- Intellectual disability or Montreal Cognitive Assessment (MoCA) score less than 20
- Visual or hearing impairments that could interfere with task performance
- Participation in psychological intervention in the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beykoz University
Istanbul, Turkey (Türkiye), 34820
Actively Recruiting
Research Team
E
Eda Yılmazer, Phd
CONTACT
M
Metin Çınaroğlu, Phd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here